HUNT'ACTIV: Adapted Physical Activity Effect on Abilities and Quality of Life of Huntington Patients and Relatives During Rehab Stay

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Recruiting
CT.gov ID
NCT04917133
Collaborator
Euromov Digital Health in Motion Montpellier France (Other)
32
1
2
20
1.6

Study Details

Study Description

Brief Summary

Intro:

Huntington's disease is a neurodegenerative disease that affects the brain, inducing a dysfunction and death of the middle spiny striatal projection neurons and a progressive alteration of cognitive and motor functions, and psycho-behavioral problems. There is currently no curative treatment but we know hat a multidisciplinary care can optimize the functioning and the quality of life of the patients with Huntington's disease.

A meta-analysis of 18studies indicates that exercise and physical activity can improve motor function, gait speed and balance, and would also improve self-confidence, independence, well-being, reduced apathy and better socialization with family and friends.

Hypothesis/Objective The hypothesis is that the inclusion of a 4 week-program with Adapted Physical Activity (APA) during a rehabilitation stay will improve some motor, cognitive and psycho-behavioral abilities, compared to the control group.

Method

The patients will be randomized into two groups :
The control group will have the "classic" program performed in the standard of care with:

kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, and creation).

The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective support : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests

For the two groups, at the start of the 4 weeks of rehabilitation program an initial visit will be performed with, as part of this research, a clinical examination, a neurological examination, a dietary consultation, as well as a biological assessment as part of habitual care.

The clinical examination, the neurological examination and the dietary consultation will be performed each week, during the 4 weeks of the program,

At the end of the study, one month after the rehabilitation of the patient, a visit by phone-call will be performed for the patient and his caregiver.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Adapted Physical Activity program
  • Other: Control
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
controlled randomized trial with two parallel armscontrolled randomized trial with two parallel arms
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effect of Adapted Physical Activity, During Rehabilitation Stay, on Abilities and Quality of Life of Huntington Patients and Their Relatives "HUNT'ACTIV-MH-REHAB MOVE MORE TO LIVE BETTER"
Actual Study Start Date :
Jun 7, 2021
Anticipated Primary Completion Date :
Feb 7, 2023
Anticipated Study Completion Date :
Feb 7, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Adapted Physical workshops

The experimental APA group will have in addition of the classic program, 6 APA workshops per week with collective care : Adapted Physical workshops, adapted cycling, therapeutic (horseback/equestrian) riding, cultural or leisure outings, situation tests

Behavioral: Adapted Physical Activity program
classic 4-week rehabilitation program (standard care) + 6 APA workshops per week with collective care

Other: Control

Standard of care The control group will have the "classic" program performed in the standard of care with : kinesitherapy, soft gym, medico-social workshop, cognitive workshop, creative workshop, individual care (rehabilitation, rest, creation).

Other: Control
classic 4-week rehabilitation program (standard care)

Outcome Measures

Primary Outcome Measures

  1. Motor function score of Unified Huntington's Disease Rating Scale (UHDRS) [Change from Baseline at 1 month]

    UHDRS:Unified Huntington's Disease Rating Scale , minimum value: 0 maximum value: 124 higher score means a worse outcome Success will be defined by an improvement of the motor function score

Secondary Outcome Measures

  1. cognitive function score of Unified Huntington's Disease Rating Scale (UHDRS) using Stroop test [Change from Baseline at 1 month]

    UHDRS:Unified Huntington's Disease Rating Scale , minimal number of correct answers:0 maximal number of correct answers:100 higher score means a better outcome Success will be defined by an improvement of the cognitive function score

  2. psycho-behavioral function score of Unified Huntington's Disease Rating Scale (UHDRS) [Change from Baseline at 1 month]

    UHDRS:Unified Huntington's Disease Rating Scale , minimum value:0 maximal value:88 higher score means a worse outcome Success will be defined by an improvement of the behavioral function score

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for the Patient :
  • Mid-stage Huntington's disease but with the ability for an autonomous walking for 10 meter

  • Age ≥ 18 years old

  • Stable medication for at least 4 weeks before the start of the study and a stable diet during the duration of the program. A stable diet means no weight loss up to 2kg in the last month prior to inclusion

  • Patient who received a complete information and who signed an informed consent for the research (or his/her caregiver if incapacity to sign). Tutor/Guardian who received a complete information and who signed an informed consent for the research if applicable

  • Affiliated to a social security scheme

Inclusion Criteria for the Caregiver :
  • Person participating in the daily life of the patient

  • The patient is included in the research

  • Age ≥ 18 years old

  • Having received a complete information

  • Non opposition collected by the investigator

Exclusion Criteria:
  • Having a physical or psychiatric condition preventing the completion of the program and assessments.

  • Having a history of additional major neurological disorders such as a stroke or an orthopedic condition limiting mobility

  • Any difficulty to understand or read French which could possibly invalidate the relevance of the application of questionnaires according to the opinion of the investigator

  • Addictions, alcohol dependence

  • Any other neurological, musculoskeletal or cardiovascular disease which could lead to errors in the assessment

  • Participation to another interventional research or being in the exclusion period following a previous research if applicable

  • Patient under AME (except if exemption from affiliation)

Exclusion criteria for the Caregiver :
  • Having a physical or psychiatric condition preventing the completion of the program and assessments.

  • Any difficulty to understand or read French which could possibly invalidate the relevance of the application of questionnaires according to the opinion of the investigator

  • Under tutelage or guardianship

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hôpital Marin de Hendaye Hendaye France 64700

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Euromov Digital Health in Motion Montpellier France

Investigators

  • Study Director: Pierre-André Natella, PhD, Assistance Publique - Hôpitaux Paris

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT04917133
Other Study ID Numbers:
  • APHP210469
  • 2021-A00423-38
First Posted:
Jun 8, 2021
Last Update Posted:
Sep 5, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2021